Jordi Esteve

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1546997/publications.pdf

Version: 2024-02-01

244 papers	9,850 citations	53794 45 h-index	42399 92 g-index
248 all docs	248 docs citations	248 times ranked	8773 citing authors

#	Article	IF	Citations
1	Prognostic impact of DNMT3A mutation in acute myeloid leukemia with mutated NPM1. Blood Advances, 2022, 6, 882-890.	5.2	15
2	Long-term results and GvHD after prophylactic and preemptive donor lymphocyte infusion after allogeneic stem cell transplantation for acute leukemia. Bone Marrow Transplantation, 2022, 57, 215-223.	2.4	36
3	Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide versus Cyclosporine A and Methotrexate in Matched Sibling Donor Transplantation. Transplantation and Cellular Therapy, 2022, 28, 86.e1-86.e8.	1.2	13
4	Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study. Blood Advances, 2022, 6, 1278-1295.	5.2	29
5	Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries. Leukemia, 2022, 36, 913-922.	7.2	23
6	Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia. Clinical Cancer Research, 2022, 28, 870-881.	7.0	32
7	Cytogenetic risk classification maintains its prognostic significance in transplanted FLT3â€ITD mutated acute myeloid leukemia patients: On behalf of the <scp>acute leukemia working party</scp>/<scp>European society of blood and marrow transplantation</scp>. American Journal of Hematology, 2022, 97, 274-282.	4.1	3
8	Results of ARI-0001 CART19 Cells in Patients With Chronic Lymphocytic Leukemia and Richterâ€™s Transformation. Frontiers in Oncology, 2022, 12, 828471.	2.8	19
9	European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Advances, 2022, 6, 1193-1206.	5.2	26
10	Results of <scp>ARI</scp>â€0001 <scp>CART19</scp> cell therapy in patients with relapsed/refractory <scp>CD19</scp>â€positive acute lymphoblastic leukemia with isolated extramedullary disease. American Journal of Hematology, 2022, 97, 731-739.	4.1	6
11	Validation of the Burkitt Lymphoma International Prognostic Index in patients treated with two prospective chemoimmunotherapy trials in Spain. Leukemia and Lymphoma, 2022, 63, 1993-1996.	1.3	2
12	Acute leukemia arising from myeloproliferative or myelodysplastic/myeloproliferative neoplasms: A series of 372 patients from the PETHEMA AML registry. Leukemia Research, 2022, 115, 106821.	0.8	3
13	PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplantation and Cellular Therapy, 2022, 28, 489.e1-489.e9.	1.2	7
14	Ponatinib, chemotherapy, and transplant in adults with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia. Blood Advances, 2022, 6, 5395-5402.	5.2	21
15	Measurable residual disease (MRD) status before allogeneic hematopoietic cell transplantation impact on secondary acute myeloid leukemia outcome. A Study from the Acute Leukemia Working Party (ALWP) of the European society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2022, 57, 1556-1563.	2.4	8
16	Management of patients with acute leukemia during the COVID-19 outbreak: practical guidelines from the acute leukemia working party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2021, 56, 532-535.	2.4	36
17	Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosomeâ€“negative adult lymphoblastic leukemia. Blood, 2021, 137, 1879-1894.	1.4	48
18	Measurable residual disease (MRD) testing for acute leukemia in EBMT transplant centers: a survey on behalf of the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 218-224.	2.4	32

#	Article	IF	Citations
19	CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19+ Relapsed/Refractory Malignancies. Molecular Therapy, 2021, 29, 636-644.	8.2	80
20	Evolving treatment patterns and outcomes in older patients (â‰¥60 years) with AML: changing everything to change nothing?. Leukemia, 2021, 35, 1571-1585.	7.2	12
21	Allogeneic stem cell transplant in patients with acute myeloid leukemia and karnofsky performance status score less than or equal to 80%: A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation (EBMT). Cancer Medicine, 2021, 10, 23-33.	2.8	7
22	Successful management of three patients with autoimmune thrombotic thrombocytopenic purpura with paradigm-changing therapy: Caplacizumab, steroids, plasma exchange, rituximab, and intravenous immunoglobulins (CASPERI). Transfusion and Apheresis Science, 2021, 60, 103011.	1.0	12
23	Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT. Bone Marrow Transplantation, 2021, 56, 1047-1055.	2.4	2
24	Better leukemia-free survival with allogeneic than with autologous HCT in AML patients with isolated trisomy 8: a study from the ALWP of the EBMT. Bone Marrow Transplantation, 2021, 56, 461-469.	2.4	2
25	The impact of cytogenetic risk on the outcomes of allogeneic hematopoietic cell transplantation in patients with relapsed/refractory acute myeloid leukemia: On behalf of the acute leukemia working party (<scp>ALWP</scp>) of the <scp>European group for blood and marrow transplantation (EBMT)</scp>. American Journal of Hematology, 2021, 96, 40-50.	4.1	10
26	Prognostic Factors in AML. Hematologic Malignancies, 2021, , 127-175.	0.2	1
27	Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. British Journal of Haematology, 2021, 192, 832-842.	2.5	15
28	Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes. Leukemia Research, 2021, 101, 106492.	0.8	0
29	Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplantÂmeasurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT. Leukemia, 2021, 35, 2232-2242.	7.2	6
30	Clinical Characteristics and Outcome of Bloodstream Infections in HIV-Infected Patients with Cancer and Febrile Neutropenia: A Caseâ€“Control Study. Infectious Diseases and Therapy, 2021, 10, 955-970.	4.0	2
31	ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma. Journal of Clinical Oncology, 2021, 39, 1317-1328.	1.6	132
32	Mutational profile of ZBTB16â€RARAâ€positive acute myeloid leukemia. Cancer Medicine, 2021, 10, 3839-3847.	2.8	9
33	Allogeneic stem cell transplantation for AML patients with RUNX1 mutation in first complete remission: a study on behalf of the acute leukemia working party of the EBMT. Bone Marrow Transplantation, 2021, 56, 2445-2453.	2.4	6
34	Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) mIDH1 acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.. Journal of Clinical Oncology, 2021, 39, 7006-7006.	1.6	8
35	Frequency, Clinical Characteristics and Outcome of Adults With Acute Lymphoblastic Leukemia and COVID 19 Infection in the First vs. Second Pandemic Wave in Spain. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e801-e809.	0.4	17
36	Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group. Leukemia and Lymphoma, 2021, 62, 2928-2938.	1.3	21

#	Article	IF	Citations
37	Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial. HemaSphere, 2021, 5, e617.	2.7	10
38	KMT2A-CBLrearrangements in acute leukemias: clinical characteristics and genetic breakpoints. Blood Advances, 2021, 5, 5617-5620.	5.2	1
39	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. Blood Cancer Journal, 2021, 11, 167.	6.2	11
40	A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 175.	6.2	3
41	Improved GvHD-Free, Relapse-Free Survival (GRFS) with Post-Transplant Cyclophosphamide and Tacrolimus for GvHD Prevention in Older Adults Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2021, 138, 2760-2760.	1.4	0
42	Design and in Vitro Evaluation of a CAR-T Prototype (ARI-0003) Targeting CD123 for Acute Myeloid Leukemia. Blood, 2021, 138, 4799-4799.	1.4	0
43	Allogeneic Hematopoietic Cell Transplantation Outcomes of Patients with R/R AML or Higher-Risk MDS Treated with the TIM-3 Inhibitor MBG453 (Sabatolimab) and Hypomethylating Agents. Blood, 2021, 138, 3677-3677.	1.4	5
44	Isocitrate Dehydrogenase (IDH) 1 and 2 Mutation Is an Independent Predictor of Better Outcome in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Study of the ALWP of EBMT. Blood, 2021, 138, 2920-2920.	1.4	1
45	Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia with Hyperdiploid Complex Karyotype: A Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2021, 138, 3952-3952.	1.4	0
46	Validation of Different Prognostic Scores in Allogeneic Hematopoietic Cell Transplantation in the Post-Transplant Cyclophosphamide Era. Blood, 2021, 138, 3925-3925.	1.4	0
47	Molecular Characteristics of Response to Olutasidenib (FT-2102) in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 2351-2351.	1.4	3
48	Sabatolimab (MBG453) Combination Treatment Regimens for Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS): The MDS Studies in the Stimulus Immuno-Myeloid Clinical Trial Program. Blood, 2021, 138, 4669-4669.	1.4	10
49	Ponatinib and Chemotherapy in Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Final Results of Ponalfil Clinical Trial. Blood, 2021, 138, 1230-1230.	1.4	4
50	Olutasidenib (FT-2102) in Combination with Azacitidine Induces Durable Complete Remissions in Patients with mIDH1 Acute Myeloid Leukemia. Blood, 2021, 138, 698-698.	1.4	7
51	Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy. Blood, 2021, 138, 700-700.	1.4	18
52	Factors associated with the clinical outcome of patients with relapsed/refractory CD19⁺ acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy. , 2021, 9, e003644.		11
53	Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 414-423.	3.5	10
54	Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1723-1730.	3.5	17

#	Article	IF	Citations
55	The impact of anti-thymocyte globulin on the outcomes of Patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation. Leukemia, 2020, 34, 1144-1153.	7.2	12
56	The impact of concomitant cytogenetic abnormalities on acute myeloid leukemia with monosomy 7 or deletion 7q after HLAâ€matched allogeneic stem cell transplantation. American Journal of Hematology, 2020, 95, 282-294.	4.1	7
57	Characteristics and outcome of adult patients with acute promyelocytic leukemia and increased body mass index treated with the PETHEMA Protocols. European Journal of Haematology, 2020, 104, 162-169.	2.2	6
58	Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoietic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years. Clinical Cancer Research, 2020, 26, 6475-6482.	7.0	40
59	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine, 2020, 383, 617-629.	27.0	1,407
60	Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone Marrow Transplantation, 2020, 55, 2244-2253.	2.4	6
61	41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo. , 2020, 8, e000845.		37
62	Acute myeloid leukemia with NPM1 mutation and favorable European LeukemiaNet category: outcome after preemptive intervention based on measurable residual disease. British Journal of Haematology, 2020, 191, 52-61.	2.5	28
63	Cytogenetic risk score maintains its prognostic significance in <scp>AML</scp> patients with detectable measurable residual disease undergoing transplantation in remission: On behalf of the acute leukemia working party of the European society for blood and marrow transplantation. American Journal of Hematology, 2020, 95, 1135-1141.	4.1	6
64	UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy. Leukemia, 2020, 34, 2925-2933.	7.2	6
65	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine Â± idasanutlin in relapsed or refractory acute myeloid leukemia. Future Oncology, 2020, 16, 807-815.	2.4	53
66	Allogeneic stem cell transplantation in AML with t(6;9)(p23;q34);DEKâ€NUP214 shows a favourable outcome when performed in first complete remission. British Journal of Haematology, 2020, 189, 920-925.	2.5	16
67	Optimised molecular genetic diagnostics of Fanconi anaemia by whole exome sequencing and functional studies. Journal of Medical Genetics, 2020, 57, 258-268.	3.2	18
68	Acute myeloid leukemia with inv(3)(q21.3q26.2)/t(3;3)(q21.3;q26.2): Study of 61 patients treated with intensive protocols. European Journal of Haematology, 2020, 105, 138-147.	2.2	12
69	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	3.5	51
70	Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2020, 105, 1507-1516.	3.5	91
71	Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplantation, 2020, 55, 1114-1125.	2.4	97
72	The STIMULUS Program: Clinical Trials Evaluating Sabatolimab (MBG453) Combination Therapy in Patients (Pts) with Higher-Risk Myelodysplastic Syndromes (HR-MDS) or Acute Myeloid Leukemia (AML). Blood, 2020, 136, 45-46.	1.4	20

#	Article	IF	Citations
73	Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients with Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndrome (HR-MDS): Updated Results from a Phase 1b Study. Blood, 2020, 136, 1-2.	1.4	54
74	PLZF-RARÎ±, NPM1-RARÎ±, and Other Acute Promyelocytic Leukemia Variants: The PETHEMA Registry Experience and Systematic Literature Review. Cancers, 2020, 12, 1313.	3.7	20
75	Myeloproliferative/Myelodysplastic Neoplasms Presenting All Diagnostic Criteria of Chronic Myelomonocytic Leukemia but with Absolute Peripheral Blood Monocytosis 0.5-1Ã— 109/L Should be Classified As CMML. Blood, 2020, 136, 10-11.	1.4	0
76	Prospective Population-Based Analysis of Characteristics and Therapy Options in AML: The Case of Catalonia (PERIS Project). Blood, 2020, 136, 32-33.	1.4	0
77	Validation of the European Leukemianet 2017 Prognostic Classification for Patients with De Novo Acute Myeloid Leukemia Treated with a Risk-Adapted Protocol (CETLAM 2012). Blood, 2020, 136, 31-32.	1.4	0
78	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Results of Ponalfil Clinical Trial after Completion of Recruitment. Blood, 2020, 136, 29-30.	1.4	1
79	Risk-Adapted Intensive Chemotherapy for Primary ACUTE Myeloid Leukemia during the Last 25 YEARS: Increase in Complete Remission RATE, Hematopoietic Cell Transplantation Access and Decrease in Relapse Incidence Have LED to Improved Survival. Blood, 2020, 136, 13-14.	1.4	0
80	Emergence ofNPM1Wild-Type Myeloid Neoplasms after Chemotherapy for Acute Leukemia withNPM1Mutation: Proposed Mechanisms of Clonal Evolution. Blood, 2020, 136, 39-40.	1.4	0
81	Sabatolimab (MBG453) Dose Selection and Dose-Response Analysis in Myelodysplastic Syndrome (MDS)/Acute Myeloid Leukemia (AML): Population Pharmacokinetics (PK) Modeling and Evaluation of Clinical Efficacy/Safety By Dose. Blood, 2020, 136, 40-42.	1.4	7
82	Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 2019, 54, 519-530.	2.4	54
83	Trends in the use of hematopoietic stem cell transplantation for adults with acute lymphoblastic leukemia in Europe: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Annals of Hematology, 2019, 98, 2389-2398.	1.8	24
84	Genomic characterization in triple-negative primary myelofibrosis and other myeloid neoplasms with bone marrow fibrosis. Annals of Hematology, 2019, 98, 2319-2328.	1.8	13
85	Molecular profiling refines minimal residual diseaseâ€based prognostic assessment in adults with Philadelphia chromosomeâ€negative Bâ€cell precursor acute lymphoblastic leukemia. Genes Chromosomes and Cancer, 2019, 58, 815-819.	2.8	6
86	Update on management and progress of novel therapeutics for R/R AML: an Iberian expert panel consensus. Annals of Hematology, 2019, 98, 2467-2483.	1.8	9
87	Dual lysosomal-mitochondrial targeting by antihistamines to eradicate leukaemic cells. EBioMedicine, 2019, 47, 221-234.	6.1	19
88	Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplantation, 2019, 54, 1295-1303.	2.4	6
89	Real life outcomes of patients aged â‰¥75 years old with acute promyelocytic leukemia: experience of the PETHEMA registry. Leukemia and Lymphoma, 2019, 60, 2720-2732.	1.3	2
90	Prognostic significance of recurring chromosomal abnormalities in transplanted patients with acute myeloid leukemia. Leukemia, 2019, 33, 1944-1952.	7.2	23

#	Article	IF	Citations
91	The poor prognosis of low hypodiploidy in adults with Bâ€cell precursor acute lymphoblastic leukaemia is restricted to older adults and elderly patients. British Journal of Haematology, 2019, 186, 263-268.	2.5	6
92	Clinical significance of complex karyotype at diagnosis in pediatric and adult patients with de novo acute promyelocytic leukemia treated with ATRA and chemotherapy. Leukemia and Lymphoma, 2019, 60, 1146-1155.	1.3	12
93	Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia â€“ a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British Journal of Haematology, 2019, 184, 782-787.	2.5	82
94	Early Tâ€cell precursor lymphoblastic leukaemia: response to <scp>FLAG</scp>â€<scp>IDA</scp> and highâ€dose cytarabine with sorafenib after initial refractoriness. British Journal of Haematology, 2019, 185, 755-757.	2.5	5
95	Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplantation, 2019, 54, 798-809.	2.4	106
96	An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens. Leukemia and Lymphoma, 2019, 60, 1030-1035.	1.3	9
97	Increased survival due to lower toxicity for highâ€risk Tâ€cell acute lymphoblastic leukemia patients in two consecutive pediatricâ€inspired PETHEMA trials. European Journal of Haematology, 2019, 102, 79-86.	2.2	14
98	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study. Blood, 2019, 134, 232-232.	1.4	17
99	Ponatinib and Chemotherapy in Young Adults with De Novo Philadelphia Chromosome-Positive Acute Lymphoblstic Leukemia. Preliminary Results of Ponalfil Clinical Trial. Blood, 2019, 134, 3874-3874.	1.4	2
100	Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia and Karnofsky Performance Status Score Equal or Lower Than 80%. a Study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2019, 134, 2038-2038.	1.4	1
101	Phase Ib Study of the Anti-TIM-3 Antibody MBG453 in Combination with Decitabine in Patients with High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). Blood, 2019, 134, 570-570.	1.4	64
102	Final Results of the AML12 Trial of the Spanish Cetlam Group in Adults with Acute Myeloid Leukemia (AML) up to the Age of 70 Years: Risk Adapted Post-Remission Allocation Based on Genetic Data and Minimal Residual Disease. Blood, 2019, 134, 289-289.	1.4	2
103	MIRROS: An ongoing randomized phase 3 trial of idasanutlin + ARA-C in patients with relapsed or refractory acute myeloid leukemia.. Journal of Clinical Oncology, 2019, 37, TPS7063-TPS7063.	1.6	8
104	Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia: In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clinical Hematology International, 2019, 1, 58.	1.7	46
105	Rituximab and Specific Therapy for Patients with Burkitt's Leukemia and Lymphoma. Results of the BURKIMAB14 Trial from the Spanish Pethema and Geltamo Groups in 80 Patients. Blood, 2019, 134, 2584-2584.	1.4	1
106	Relapse and survival after transplantation for complex karyotype acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer, 2018, 124, 2134-2141.	4.1	30
107	Tâ€cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3â€ITD in acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology, 2018, 93, 736-744.	4.1	21
108	AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation. Bone Marrow Transplantation, 2018, 53, 683-691.	2.4	13

#	Article	IF	Citations
109	A 4-gene expression prognostic signature might guide post-remission therapy in patients with intermediate-risk cytogenetic acute myeloid leukemia. Leukemia and Lymphoma, 2018, 59, 2394-2404.	1.3	16
110	Bone marrowVEGFCexpression is associated with multilineage dysplasia and several prognostic markers in adult acute myeloid leukemia, but not with survival. Leukemia and Lymphoma, 2018, 59, 2383-2393.	1.3	1
111	A phase Iâ€"II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia. Annals of Hematology, 2018, 97, 763-772.	1.8	39
112	Allogeneic stem cell transplantation benefits for patients â‰¥ 60 years with acute myeloid leukemia and FLT3 internal tandem duplication: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2018, 103, 256-265.	3.5	18
113	Comparison of intensive, pediatric-inspired therapy with non-intensive therapy in older adults aged 55â€"65 years with Philadelphia chromosome-negative acute lymphoblastic leukemia. Leukemia Research, 2018, 68, 79-84.	0.8	9
114	Validation of a routine gas chromatography mass spectrometry method for 2-hydroxyglutarate quantification in human serum as a screening tool for detection of idh mutations. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 28-34.	2.3	11
115	Relatively favorable outcome after allogeneic stem cell transplantation for BCRâ€ABL1â€positive AML: A survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). American Journal of Hematology, 2018, 93, 31-39.	4.1	13
116	Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study. Blood Advances, 2018, 2, 2127-2135.	5.2	34
117	Risk factors for mortality in patients with acute leukemia and bloodstream infections in the era of multiresistance. PLoS ONE, 2018, 13, e0199531.	2.5	60
118	Comparable outcomes of haploidentical, 10/10 and 9/10 unrelated donor transplantation in adverse karyotype AML in first complete remission. American Journal of Hematology, 2018, 93, 1236-1244.	4.1	40
119	Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study. Biology of Blood and Marrow Transplantation, 2018, 24, 1406-1414.	2.0	44
120	Multicenter, Open-Label, 3-Arm Study of Gilteritinib, Gilteritinib Plus Azacitidine, or Azacitidine Alone in Newly Diagnosed FLT3 Mutated (FLT3mut+) Acute Myeloid Leukemia (AML) Patients Ineligible for Intensive Induction Chemotherapy: Findings from the Safety Cohort. Blood, 2018, 132, 2736-2736.	1.4	44
121	Post-Transplant Sorafenib Improves Overall Survival in FLT3 Mutated AML: A Report from the EBMT Acute Leukemia Working Party. Blood, 2018, 132, 708-708.	1.4	4
122	Prognostic Impact of the Interaction between DNMT3A mutation and Internal Tandem Duplication of the FLT3 Gene (FLT3-ITD) in Patients with De Novo Mutated NPM1 (NPM1mut) acute Myeloid Leukemia. Blood, 2018, 132, 1492-1492.	1.4	0
123	Therapy-Related MDS Can be Separated into Different Risk-Groups According to Tools for Classification and Prognostication of Primary MDS. Blood, 2018, 132, 3103-3103.	1.4	0
124	The Role of Anti-Thymocyte Globulin (ATG) in Patients with AML Transplanted in CR1 from Sibling and Unrelated Donors with or without Measurable Residual Disease (MRD) at the Time of Allogeneic Stem Cell Transplantation: A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Blood, 2018, 132, 248-248.	1.4	1
125	Triple Negative Myelofibrosis and Myelodysplastic Syndrome with Fibrosis: Clinico-Biological Characterization and Correlation with Gene Mutations. Blood, 2018, 132, 4299-4299.	1.4	0
126	Favorable Outcome in Patients with Acute Myeloblastic Leukemia (AML) with NPM1 Mutation Who Present an Inadequate Clearance or Relapse of Minimal/Measurable Residual Disease (MRD): Results of a Preemptive Intervention Policy (CETLAM-2012 Protocol). Blood, 2018, 132, 1385-1385.	1.4	1

#	Article	IF	Citations
127	FLT3 and NPM1 Are Powerful Determinants of Outcome in Acute Myeloid Leukemia Patients Treated with Autologous Stem Cell Transplantation: An Analysis By the Acute Leukemia Working Party of the EBMT. Blood, 2018, 132, 609-609.	1.4	0
128	The Impact of Cytogenetics on the Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Relapsed/Refractory Acute Myeloid Leukemia: A Survey from the Acute Leukemia Working Party (ALWP) of EBMT. Blood, 2018, 132, 4639-4639.	1.4	0
129	Assessment of Bone Health in Patients With Type 1 Gaucher Disease Using Impact Microindentation. Journal of Bone and Mineral Research, 2017, 32, 1575-1581.	2.8	13
130	Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Journal of Hematology and Oncology, 2017, 10, 20.	17.0	43
131	ABO incompatibility in mismatched unrelated donor allogeneic hematopoietic cell transplantation for acute myeloid leukemia: A report from the acute leukemia working party of the EBMT. American Journal of Hematology, 2017, 92, 789-796.	4.1	17
132	Anti-thymocyte globulin as graft- versus -host disease prevention in the setting of allogeneic peripheral blood stem cell transplantation: a review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 224-234.	3.5	108
133	Mixed phenotype acute leukemia: outcomes with allogeneic stem cell transplantation. A retrospective study from the Acute Leukemia Working Party of the EBMT. Haematologica, 2017, 102, 2134-2140.	3.5	33
134	Haploidentical hematopoietic cell transplantation for adult acute myeloid leukemia: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica, 2017, 102, 1810-1822.	3.5	64
135	Clinical and biological significance of isolated Y chromosome loss in myelodysplastic syndromes and chronic myelomonocytic leukemia. A report from the Spanish MDS Group. Leukemia Research, 2017, 63, 85-89.	0.8	9
136	Myeloablative Versus Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia in Patients with Prior Myelodysplastic Syndrome/ Myeloproliferative Disorders: An ALWP of EBMT Study. Blood, 2017, 130, 907-907.	1.4	0
137	Allogeneic Hematopoietic Cell Transplantation (alloHCT) for Adult Patients with t(4;11)(q21;q23) KMT2A/AFF1 (MLL/AF4) B-Acute Lymphoblastic Leukemia in First Complete Remission (CR1): Favorable Outcome of Patients with Negative Minimal Residual Disease (MRD) Status at Transplant. a Report from the Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation (ALWP-EBMT). Blood, 2017, 130, 660-660.	1.4	0
138	Haploidentical T-Repleted Stem Cell Transplantation (SCT) Has Comparable Survival to 10/10 and 9/10 Unrelated SCT in Poor-Cytogenetics Risk Acute Myeloid Leukemia in First Complete Remission: A Study on Behalf of the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT). Blood, 2017, 130, 852-852.	1.4	0
139	RIC versus MAC UCBT in adults with AML: A report from Eurocord, the ALWP and the CTIWP of the EBMT. Oncotarget, 2016, 7, 43027-43038.	1.8	40
140	Peripheral blood stem cell graft compared to bone marrow after reduced intensity conditioning regimens for acute leukemia: a report from the ALWP of the EBMT. Haematologica, 2016, 101, 256-262.	3.5	42
141	Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosomeâ€“positive acute lymphoblastic leukemia: A position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer, 2016, 122, 2941-2951.	4.1	140
142	Allogeneic hematopoietic cell transplantation in acute myeloid leukemia with normal karyotype and isolated Nucleophosmin-1 (NPM1) mutation: outcome strongly correlates with disease status. Haematologica, 2016, 101, e34-e37.	3.5	12
143	Expanding transplant options to patients over 50 years. Improved outcome after reduced intensity conditioning mismatched-unrelated donor transplantation for patients with acute myeloid leukemia: a report from the Acute Leukemia Working Party of the EBMT. Haematologica, 2016, 101, 773-780.	3.5	35
144	Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT. Haematologica, 2016, 101, 248-255.	3.5	19

#	Article	IF	Citations
145	Prognostic impact of chromosomal translocations in myelodysplastic syndromes and chronic myelomonocytic leukemia patients. A study by the spanish group of myelodysplastic syndromes. Genes Chromosomes and Cancer, 2016, 55, 322-327.	2.8	7
146	Romiplostim for the treatment of glioblastoma-related paraneoplastic autoimmune thrombocytopenia refractory to conventional therapy. Annals of Hematology, 2016, 95, 665-666.	1.8	2
147	Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2016, 128, 112-112.	1.4	2
148	Prediction of Hematopoietic Stem Cell Transplantation Related Mortality- Lessons Learned from the In-Silico Approach: A European Society for Blood and Marrow Transplantation Acute Leukemia Working Party Data Mining Study. PLoS ONE, 2016, 11, e0150637.	2.5	28
149	Isolate Loss of Y Chromosome Decreases the Risk of Leukemic Transformation in the Myelodysplastic Syndromes. a Study By the Spanish Group of Myelodysplastic Syndromes. Blood, 2016, 128, 4331-4331.	1.4	0
150	Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood, 2015, 126, 2062-2069.	1.4	93
151	Treatment with G-CSF reduces acute myeloid leukemia blast viability in the presence of bone marrow stroma. Cancer Cell International, 2015, 15, 122.	4.1	4
152	Comparison of three prognostic scoring systems in a series of 146 cases of chronic myelomonocytic leukemia (CMML): MD Anderson prognostic score (MDAPS), CMML-specific prognostic scoring system (CPSS) and Mayo prognostic model. A detailed review of prognostic factors in CMML. Leukemia Research, 2015, 39, 1146-1153.	0.8	15
153	Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica, 2015, 100, 392-399.	3.5	139
154	Complex Measurements May Be Required to Establish the Prognostic Impact of Immunophenotypic Markers in AML. American Journal of Clinical Pathology, 2015, 144, 484-492.	0.7	13
155	Longâ€term followâ€up of doseâ€adjusted EPOCH plus rituximab (DAâ€EPOCHâ€R) in untreated patients with poor prognosis large Bâ€cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group. British Journal of Haematology, 2015, 169, 188-198.	2.5	49
156	Chemotherapy Dose Adjustment for Obese Patients Undergoing Hematopoietic Stem Cell Transplantation: A Survey on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Oncologist, 2015, 20, 50-55.	3.7	9
157	Post-Remission Treatment with Chemotherapy or Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-neg) Adult Acute Lymphoblastic Leukemia (ALL) According to Minimal Residual Disease (MRD). Preliminary Results of the Pethema ALL-HR-11 Trial. Blood, 2015, 126, 1333-1333.	1.4	9
158	Incidence, Treatment and Prognosis of Patients with Relapsed Burkitt Lymphoma/Leukemia Treated with Specific Chemotherapy or Immunochemotherapy in Spain. Blood, 2015, 126, 2723-2723.	1.4	1
159	An Analysis of Prognostic Markers and the Performance of Scoring Systems in 1837 Patients with Therapy-Related Myelodysplastic Syndrome - a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes (MDS). Blood, 2015, 126, 609-609.	1.4	5
160	Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 63-63.	1.4	1
161	Efficacy, Safety and Long Term Results of Prophylactic and Preemptive Donor Lymphocyte Infusion after Allogeneic Stem Cell Transplantation for Acute Leukemia: A Registry-Based Evaluation on 343 Patients By the Acute Leukemia Working Party of EBMT. Blood, 2015, 126, 863-863.	1.4	23
162	The lincRNAHOTAIRM1, located in theHOXAgenomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature. Oncotarget, 2015, 6, 31613-31627.	1.8	78

#	Article	IF	Citations
163	Allogeneic Stem Cell Transplantation for Elderly Patients with Intermediate-Risk Cytogenetic Acute Myeloid Leukemia and Internal Tandem Duplication of FLT3 (FLT3-ITD); A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 4364-4364.	1.4	0
164	Disease-Attributable Mortality in the Myelodysplastic Syndromes (MDS): A Study from the Spanish MDS Cooperative Group (GESMD). Blood, 2015, 126, 1672-1672.	1.4	0
165	Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation. Blood, 2015, 126, 155-155.	1.4	0
166	Allogeneic Stem Cell Transplantation in Adult Patients with Acute Myeloid Leukemia and 17p Abnormalities in First Complete Remission: A Study from the Acute Leukemia Working Party (ALWP) of the European Society of Blood and Marrow Transplantation (EBMT). Blood, 2015, 126, 2021-2021.	1.4	0
167	Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT. Blood, 2015, 126, 196-196.	1.4	0
168	Favorable Outcome of Older Patients with AML and a Favorable Genotype NPM1mut FLT3-ITD Treated with Intensive Chemotherapy: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2511-2511.	1.4	0
169	Prognostic Impact of MLL Partial Tandem Duplication in Acute Myeloid Leukemia of Intermediate Cytogenetic Risk: A Subgroup Analysis of Cetlam Protocol 2003 & 2012. Blood, 2015, 126, 2514-2514.	1.4	0
170	High levels of global DNA methylation are an independent adverse prognostic factor in a series of 90 patients with de novo myelodysplastic syndrome. Leukemia Research, 2014, 38, 874-881.	0.8	16
171	Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. Journal of Antimicrobial Chemotherapy, 2014, 69, 2556-2562.	3.0	39
172	Phase II trial to assess the safety and efficacy of clofarabine in combination with low-dose cytarabine in elderly patients with acute myeloid leukemia. Annals of Hematology, 2014, 93, 43-46.	1.8	16
173	Multilineage dysplasia is associated with a poorer prognosis in patients with de novo acute myeloid leukemia with intermediate-risk cytogenetics and wild-type NPM1. Annals of Hematology, 2014, 93, 1695-1703.	1.8	25
174	Treatment of High-Risk Philadelphia Chromosomeâ€“Negative Acute Lymphoblastic Leukemia in Adolescents and Adults According to Early Cytologic Response and Minimal Residual Disease After Consolidation Assessed by Flow Cytometry: Final Results of the PETHEMA ALL-AR-03 Trial. Journal of Clinical Oncology, 2014, 32, 1595-1604.	1.6	227
175	Piwirna-651 Expression Influences Treatment Response and Impacts Survival in Classical Hodgkin Lymphoma Patients through Regulation of ABCC5. Blood, 2014, 124, 134-134.	1.4	4
176	Prediction of Allogeneic HSCT Related Mortality in Acute Leukemia: Exploring Boundaries of Prediction through Machine Learning Based Modeling. a Data Mining Study from the Acute Leukemia Working Party (ALWP) of the EBMT. Blood, 2014, 124, 2568-2568.	1.4	2
177	Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) in First Complete Remission Is Superior Compared to Chemotherapy/Autologous HSCT in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia Lacking Mutations in NPM1, FLT3-ITD, and CEBPA: A Joint Study of AMLSG, Cetlam and Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 324-324.	1.4	2
178	At-Home Management of Adult Patients Following Consolidation Chemotherapy for Acute Myeloid Leukemia. Blood, 2014, 124, 3692-3692.	1.4	4
179	The LincRNA HOTAIRM1, Located in the HOXA genomic Region, impacts Prognosis in Acute Myeloid Leukemia and Is Associated with a Distinctive microRNA Signature. Blood, 2014, 124, 1003-1003.	1.4	0
180	Comparison of Three Prognostic Scoring Systems in a Series of 146 Cases of Chronic Myelomonocytic Leukemia (CMML): MD Anderson Prognostic Score (MDAPS), CMML-Specific Prognostic Scoring System (CPSS) and Mayo Prognostic Model. Blood, 2014, 124, 4660-4660.	1.4	0

#	Article	IF	Citations
181	Clinical Features and Prognostic Assessment in 233 Patients with Therapy-Related Myelodysplastic Syndromes: The IPSS-R Is a Powerful Predictor of Outcome. Blood, 2014, 124, 4636-4636.	1.4	0
182	Genetic Markers Add Significant Prognostic Information to Age and WBC Count in High-Risk, Ph-Negative, B-Precursor Adult Acute Lymphoblastic Leukemia (ALL): Study of 96 Patients Treated According to Risk-Adapted Protocols from the Pethema Group. Blood, 2014, 124, 3798-3798.	1.4	0
183	Allogeneic Hematopoietic Cell Transplantation in AML with Normal Karyotype and NPM1 Mutated FLT3-ITD Negative: A Retrospective Analysis from the Acute Leukemia Working Party of EBMT. Blood, 2014, 124, 1230-1230.	1.4	1
184	Reply. Journal of the American College of Cardiology, 2013, 62, 2452.	2.8	10
185	Enalapril and Carvedilol for Preventing Chemotherapy-Induced Left Ventricular Systolic Dysfunction in Patients With Malignant Hemopathies. Journal of the American College of Cardiology, 2013, 61, 2355-2362.	2.8	519
186	Doseâ€intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status. Cancer, 2013, 119, 1660-1668.	4.1	63
187	Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood, 2013, 121, 2734-2738.	1.4	246
188	Evaluation Of Two Prognostic Scoring Systems For Chronic Myelomonocytic Leukemia (CMML): CMML-Specific Prognostic Scoring System (CPSS) and MD Anderson Prognostic Score (MDAPS) In A Series Of 122 Cases Of De Novo CMML. Blood, 2013, 122, 2810-2810.	1.4	2
189	Prognostic Significance Of a 4-Microrna Signature Targeting JAK2 In Classical Hodgkin Lymphoma. Blood, 2013, 122, 629-629.	1.4	4
190	Extreme Heterogeneity Of Myeloablative Total Body Irradiation (TBI) Techniques Across Europe: A Survey Of Acute Leukemia Working Party Of The EBMT. Blood, 2013, 122, 4565-4565.	1.4	0
191	Prediction Of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Related Mortality in Acute Leukemia: Generation Of a Machine Learning-Based Model Using The Data Set of The Acute Leukemia Working Party (ALWP) Of The EBMT. Blood, 2013, 122, 409-409.	1.4	5
192	DNMT3A Mutation May Add Prognostic Value To Patients With Acute Myeloid Leukemia Of Intermediate Cytogenetic Risk Harboring a Favorable Genetic Profile Of NPM1, FLT3-ITD and CEBPA. Blood, 2013, 122, 1339-1339.	1.4	0
193	BAALC-Associated Mir-3151 Is An Independent Prognostic Factor In Younger Patients With Intermediate-Risk Cytogenetic Acute Myeloid Leukemia. Blood, 2013, 122, 2577-2577.	1.4	0
194	Chemotherapy Dose Adjustment For Obese Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Survey On Behalf Of The ALWP Of The EBMT. Blood, 2013, 122, 4535-4535.	1.4	0
195	Long-Term Outcome Of 151 Patients With Relapsed APL Receiving Second-Line With Chemotherapy Or Arsenic Trioxide-Based Regimens. Blood, 2013, 122, 3922-3922.	1.4	0
196	Treatment With G-CSF Reduces Acute Myeloid Leukemia (AML) Blasts Viability In Presence Of Bone Marrow Stroma. Blood, 2013, 122, 1422-1422.	1.4	0
197	Intensive Immunochemotherapy In Patients With B-Cell Lymphoma, Unclassifiable (B-UCL), With Features Intermediate Between Diffuse Large B-Cell Lymphoma (DLBCL) and Burkitt Lymphoma (BL): A Comparison With BL Patients Treated With The Same Protocol In The Pethema-Burkimab-04 Trial. Blood, 2013, 122, 1793-1793.	1.4	1
198	Allogeneic Stem Cell Transplantation For Acute Myeloid Leukemia With Normal Cytogenetics (CN-AML): Outcome, Risk Factors and Role Of Molecular Subgroups In 752 Patients â€“ A Report From The Acute Leukemia Working Party Of EBMT. Blood, 2013, 122, 921-921.	1.4	0

#	Article	IF	Citations
199	Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis. Journal of Clinical Oncology, 2012, 30, 735-741.	1.6	251
200	Prevention of Chemotherapy-Induced Left Ventricular Dysfunction With Enalapril and Carvedilol: Rationale and Design of the OVERCOME Trial. Journal of Cardiac Failure, 2011, 17, 643-648.	1.7	26
201	Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood, 2011, 117, 1799-1805.	1.4	112
202	The Influence of Monosomal Karyotype On Survival in Patients with Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Survey On Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2011, 118, 158-158.	1.4	2
203	Outcome of Allogeneic Hematopoietic Stem-Cell Transplantation for Acute Myeloid Leukemia (AML) with 11q23 (MLL) Rearrangement (MLL-r AML). A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. Blood, 2011, 118, 498-498.	1.4	0
204	Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) for Philadelphia Chromosome Acute Lymphoblastic Leukemia (Ph+ALL) in First Complete Remission (CR1) At the Era of Tyrosine Kinase Inhibitors (TKI): A Survey From the Acute Leukemia Working Party (ALWP) of EBMT,. Blood, 2011, 118, 4107-4107.	1.4	0
205	Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. Blood, 2010, 115, 5137-5146.	1.4	278
206	Therapy-Related Myeloid Neoplasms in Patients With Acute Promyelocytic Leukemia Treated With All-Trans-Retinoic Acid and Anthracycline-Based Chemotherapy. Journal of Clinical Oncology, 2010, 28, 3872-3879.	1.6	74
207	Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica, 2010, 95, 87-95.	3.5	164
208	Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica, 2010, 95, 589-596.	3.5	240
209	A Distinctive MicroRNA Signature Characterizes Acute Myeloid Leukemia with Translocation (8;16)(p11;p13) and MYST3-CREBBP Rearrangement. Blood, 2010, 116, 230-230.	1.4	1
210	Allogeneic Hematopoietic Stem-Cell Transplantation In Early Phase Might Overcome the Adverse Prognosis of Acute Myeloid Leukemia with Translocation t(6;9)(p23;q34)/DEK-NP214(CAN) Rearrangement. A Retrospective Analysis From the Acute Leukemia Working Party of EBMT. Blood, 2010, 116, 3501-3501.	1.4	1
211	Impact of the Presence of An Internal Tandem Duplicate of FLT3 Receptor (ITD) on the Outcome of Adult Patients with Acute Myelocytic Leukemia (AML) Autografted In First Remission (CR1)Norbert-Claude Gorin, Myriam Labopin, Jordi Esteve, and Mohamad Mohty, on Behalf of the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Blood, 2010, 116, 3556-3556.	1.4	0
212	Central nervous system involvement at first relapse in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy without intrathecal prophylaxis. Haematologica, 2009, 94, 1242-1249.	3.5	93
213	Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors. Blood, 2009, 113, 775-783.	1.4	279
214	Assessment of CEBPA Mutations Might Contribute to a Better Prognostic Assignment in Patients with Intermediate-Risk Cytogenetics Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 2611-2611.	1.4	0
215	Highâ€dose chemotherapy and immunotherapy in adult Burkitt lymphoma. Cancer, 2008, 113, 117-125.	4.1	122
216	Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. Blood, 2008, 111, 1078-1084.	1.4	156

#	Article	IF	Citations
217	Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood, 2008, 111, 3395-3402.	1.4	303
218	Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood, 2008, 112, 3130-3134.	1.4	154
219	Reduced Intensity Versus Conventional Myeloablative Conditioning (RIC vs. MAC) Allogeneic Stem Cell Transplantation (allo-SCT) for Patients with Acute Lymphoblastic Leukemia (ALL): A Survey from the Acute Leukemia Working Party of EBMT. Blood, 2008, 112, 793-793.	1.4	4
220	A Prospective Study on the Feasibility of Related and Unrelated Donor Search and Hematopoietic Cell Transplantation for Adults with Acute Leukemia at 31 European Transplant Centers. Blood, 2008, 112, 2385-2385.	1.4	0
221	The role of stem-cell transplantation in chronic lympocytic leukemia risk-adapted therapy. Best Practice and Research in Clinical Haematology, 2007, 20, 529-543.	1.7	9
222	Prolonged survival of patients with angioimmunoblastic Tâ€cell lymphoma after highâ€dose chemotherapy and autologous stem cell transplantation. The GELTAMO experience. European Journal of Haematology, 2007, 78, 290-296.	2.2	59
223	Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Updated Results of the Spanish PETHEMA LPA99 Trial Using ATRA and Anthracycline Monochemotherapy.. Blood, 2007, 110, 590-590.	1.4	1
224	How I treat refractory CLL. Blood, 2006, 107, 1276-1283.	1.4	85
225	Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia. Blood, 2006, 107, 4563-4569.	1.4	130
226	Genetic abnormalities and clinical outcome in chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2006, 171, 57-64.	1.0	52
227	Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration. European Journal of Haematology, 2006, 77, 486-492.	2.2	30
228	Incidence and Risk Factors for Thrombosis in Patients with Acute Promyelocytic Leukemia. Experience of the PETHEMA LPA96 and LPA99 Protocols.. Blood, 2006, 108, 1503-1503.	1.4	19
229	Retinoic Acid Syndrome in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Anthracycline Monochemotherapy.. Blood, 2006, 108, 2010-2010.	1.4	0
230	Gene Expression Signature of Acute Myeloid Leukemia (AML) with T(8;16)(P11;P13) and MYST3-CREBBP Rearrangement: A Microarray Study Validated by Multiple Real-Time PCR.. Blood, 2005, 106, 3009-3009.	1.4	0
231	All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Blood, 2004, 104, 3490-3493.	1.4	98
232	Gene Expression Profile of Acute Myeloid Leukemia (AML) with t(8;16)(p11;p13) and MYST3/CREBBP Rearrangement.. Blood, 2004, 104, 2054-2054.	1.4	0
233	Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica, 2004, 89, 832-6.	3.5	100
234	Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthracycline monochemotherapy: a multicenter study by the PETHEMA group. Blood, 2003, 103, 1237-1243.	1.4	395

#	Article	IF	Citations
235	Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 2002, 119, 976-984.	2.5	163
236	Thalidomide in multiple myeloma: lack of response of softâ€tissue plasmacytomas. British Journal of Haematology, 2001, 113, 422-424.	2.5	73
237	Prognostic features and outcome in patients with diffuse large B-cell lymphoma who do not achieve a complete response to first-line regimens. Cancer, 2001, 91, 1557-1562.	4.1	22
238	Hybrid chemotherapy consisting of cyclophosphamide, vincristine, procarbazine, prednisone, doxorubicin, bleomycin, and vinblastine (C-MOPP/ABV) as first-line treatment for patients with advanced hodgkin disease. , 2000, 88, 2142-2148.		17
239	Expression of potentially oncogenic HHV-8 genes in an EBV-negative primary effusion lymphoma occurring in an HIV-seronegative patient. , 1999, 189, 288-293.		44
240	â€˜Lymphoidâ€™ blast crisis of chronic myeloid leukaemia is associated with distinct clinicohaematological features. British Journal of Haematology, 1998, 100, 129-134.	2.5	79
241	The changing profile of idiopathic myelofibrosis: a comparison of the presenting features of patients diagnosed in two different decades. European Journal of Haematology, 1998, 60, 101-105.	2.2	36
242	Risk of relapse and clinicoâ€pathological features in 103 patients with diffuse largeâ€cell lymphoma in complete response after firstâ€line treatment. European Journal of Haematology, 1998, 61, 59-64.	2.2	11
243	Identification of â€˜shortâ€livedâ€™ and â€˜longâ€livedâ€™ patients at presentation of idiopathic myelofibrosis. British Journal of Haematology, 1997, 97, 635-640.	2.5	164
244	Long-term outcomes in patients with relapsed/refractory acute myeloid leukemia and other high-risk myeloid malignancies after undergoing sequential conditioning regimen based on IDA-FLAG and high-dose melphalan. Bone Marrow Transplantation, 0, , .	2.4	1